Reagena

What Reagena does

Reagena is a privately-held Finnish in vitro diagnostics company headquartered in Toivala (Siilinjärvi), Kuopio region, with a 35-year operating history dating to 1987 (originally Erilab) and the Reagena name adopted in 2003. The company develops, manufactures, and sells CE-marked diagnostic tests and laboratory reagents under ISO 9001:2015 and ISO 13485:2016 quality systems, with current good standing under the EU IVD Regulation (IVDR 2017/746). Its product portfolio centers on lateral flow rapid tests and enzyme immunoassays (EIA/ELISA) for zoonotic infectious diseases—specifically hantaviruses (Puumala, Dobrava/Hantaan), Lyme borreliosis (including neuroborreliosis via CXCL13), and tick-borne encephalitis (TBE)—read on the proprietary ReaScan+ reader platform or visually (Reagena POC). Reagena also manufactures staining solutions, fixatives, Ph.Eur. reagents, and industrial buffers, and operates a contract manufacturing business for diagnostic reagents, controls, calibrators, and EIA plates.

Reagena serves three primary customer segments: (1) hospitals, reference laboratories, and physicians using its own diagnostic tests; (2) industrial and pharmaceutical customers purchasing reagents and contract-manufactured products; and (3) Finnish B2B customers purchasing EUROIMMUN (PerkinElmer) and Beckman Coulter Diagnostics products through exclusive distribution agreements held since 2018 and 2019 respectively. Revenue is generated through one-time product sales across five streams: own diagnostic products, laboratory reagents, contract manufacturing, third-party distribution, and a Finnish B2B e-commerce storefront (kauppa.reagena.com). Distribution is mixed: direct sales and e-commerce in Finland, and a network of named distribution partners across 30+ countries in Europe (Aidian in Nordics, DiaSorin in France, AlphaScience in DACH, Syngen Biotech in Poland, Selinion Medical in Benelux, etc.). The company is currently investing in mobile-readable diagnostic platforms, with a Mobile Readable CRP Test in regulatory phase as of 2025, alongside fresh CTO and product development engineering leadership.

Name

Reagena

Legal name

Reagena Oy

Website

https://reagena.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

11–50 employees

Short description

Reagena is a Finnish in vitro diagnostics company that develops, manufactures, and sells CE-marked rapid tests and EIA kits for zoonotic diseases (hantavirus, Lyme, TBE), laboratory reagents, and contract manufacturing services, and is the exclusive Finnish distributor of EUROIMMUN and Beckman Coulter Diagnostics products.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB), Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)

Keywords

• Infectious disease diagnostics
• Rapid diagnostic tests
• Zoonotic disease testing
• Laboratory reagents
• Contract manufacturing

Headquarters

HQ city

Toivala

HQ country

Finland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Own Diagnostic Products (Rapid Tests & EIA): Revenue from manufacturing and selling proprietary diagnostic products including ReaScan+ rapid tests, Reagena POC rapid tests, and EIA test kits for hantaviruses (Puumala, Dobrava/Hantaan), Lyme disease, TBE, and CXCL13. Products are sold through distributors across 30+ countries and directly in Finland.
2. Laboratory Reagents: Revenue from manufacturing and selling staining solutions, fixatives, buffers, indicators, and other reagents for hematology, microbiology, cytology, and pathology. CE marked under IVDR. Sold through distributors and direct B2B channels.
3. Contract Manufacturing: Reagena provides contract manufacturing services for diagnostic products including reagents, controls, calibrators, and EIA plates for industrial customers. Products are manufactured according to customer specifications and quality requirements, with packaging and labeling included.
4. Distribution Products (EUROIMMUN & Beckman Coulter): Revenue from distributing third-party diagnostic products in Finland. Reagena has been the exclusive distributor for EUROIMMUN products (autoimmune, infectious diseases, allergies, genetics) since 2018, and for Beckman Coulter Diagnostics products since 2019.
5. E-commerce (B2B): Revenue from the company's Finnish e-commerce platform (kauppa.reagena.com) selling directly to B2B customers including pharmacies, laboratories, and industrial clients. Products include diagnostics, staining solutions, industrial/laboratory solutions, and pharmacopeia reagents.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Reagena develops, manufactures, and sells in vitro diagnostic (IVD) products specializing in rapid tests for zoonotic infectious diseases including hantavirus (Puumala, Dobrava/Hantaan), Lyme disease, tick-borne encephalitis (TBE), and CXCL13 chemokine testing. The portfolio comprises the ReaScan+ reader-based rapid tests, Reagena POC visual rapid tests, and Reagena EIA enzyme immunoassays, complemented by laboratory reagents (staining solutions, fixatives, buffers) and contract manufacturing services for diagnostic products. The company also serves as the exclusive Finnish distributor for EUROIMMUN and Beckman Coulter Diagnostics products.

Product overview

Reagena is a Finnish in vitro diagnostics company specializing in rapid diagnostic tests for zoonotic diseases, primarily tick-borne and rodent-borne infections. The product portfolio consists of three main categories: (1) ReaScan+ rapid tests read by the ReaScan+ reader device for Puumala virus, TBE, Lyme disease (IgM/IgG Combo, C6 IgG), CXCL13, and Dobrava-Hantaan virus; (2) Reagena POC visual rapid tests for Puumala virus; (3) Reagena EIA enzyme immunoassays for Puumala and Dobrava/Hantaan viruses. The company also manufactures laboratory reagents including staining solutions, fixatives, Ph.Eur reagents, and industrial buffers, and serves as exclusive Finnish distributor for EUROIMMUN and Beckman Coulter diagnostic products. Reagena offers contract manufacturing services for diagnostic products and is developing mobile-readable diagnostic solutions.

Differentiator

Problem solved

Functional benefit

Brands

• ReaScan+: Rapid test product family with reader technology for detection of Hantavirus, TBE, Lyme, and CXCL13 infections. Provides reportable and reliable results in 20 minutes.
• Reagena POC
• ReaScan

Products and services

• ReaScan+ Reader A compact rapid test reader device with an intuitive graphical user interface that delivers reportable and reliable results in 20 minutes. Connects to Laboratory Information Systems (LIS) via the ReaScan+ Connect Server software for workflow integration. Compatible with ReaScan+ rapid tests for Puumala, TBE, C6 LYME IgG, CXCL13, and DOBRAVA-HANTAAN.
• ReaScan+ PUUMALA IgM Immunochromatographic rapid test for qualitative detection of Puumala virus specific IgM antibodies from human serum and plasma. PPA 99.3%, NPA 99.3% (275 samples tested). Result read with ReaScan+ reader in 15 minutes.
• ReaScan TBE IgM Immunochromatographic rapid test for qualitative detection of tick-borne encephalitis (TBE/FSME) virus specific IgM antibodies in human serum and cerebrospinal fluid (CSF). Specificity 98% and Sensitivity 99% (serum); Specificity 100% and Sensitivity 92% (CSF).
• ReaScan DOBRAVA-HANTAAN IgM Lateral flow rapid test for detection of acute Hantavirus infections (Dobrava and Hantaan) in human serum or plasma. NPA 100%, PPA 96%.
• ReaScan+ C6 LYME IgG Immunochromatographic rapid test for qualitative detection of Borrelia burgdorferi specific IgG antibodies in human serum and cerebrospinal fluid. Specificity 95%, Sensitivity 97% (serum).
• ReaScan+ LYME IgM/IgG Combo Immunochromatographic rapid test using two synthetic peptide antigens (C6 (VlsE) and PepC10 (OspC)) in separate test lines, detecting both IgM and IgG antibodies against Borrelia burgdorferi. Suitable for diagnostics of both early and disseminated Lyme borreliosis. PPA 94.8%, NPA 95.6% (CSF, serum/plasma).
• ReaScan CXCL13 Immunochromatographic rapid test for semiquantitative determination of chemokine CXCL13 in human cerebrospinal fluid (CSF) for Lyme neuroborreliosis diagnosis. Specificity 96%, Sensitivity 100% (CSF) with cut-off 250 pg/mL.
• Reagena POC PUUMALA IgM Visual point-of-care rapid test for detection of Puumala virus specific IgM antibodies from serum, plasma, or fingertip blood. Easy 3-step procedure with 10–15 minute result reading. Specificity 98.4%, Sensitivity 93.1%. On the market for over 20 years.
• Reagena C6 LYME IgM/IgG EIA Enzyme immunoassay for qualitative detection of Borrelia burgdorferi specific IgM and IgG antibodies in human serum and cerebrospinal fluid. PPA 92.7%, NPA 95.9%. 96 tests per package.
• Reagena PUUMALA IgM EIA Enzyme immunoassay for detection of acute Puumala virus infection from human serum. Uses µ-chain specific antibodies on microtiter plate with HRP detection. Total incubation time 2.5 hours. Specificity 100%, Sensitivity 99%.
• Reagena PUUMALA IgG EIA Enzyme immunoassay for detection of Puumala IgG antibodies from human serum. Specificity 98.96%, Sensitivity 95.24%. 96 wells per package.
• Reagena DOBRAVA-HANTAAN IgM EIA Enzyme immunoassay for detection of acute Dobrava and Hantaan virus infection from human serum. Uses µ-chain specific antibodies with HRP detection. Total incubation time 2.5 hours.
• Reagena DOBRAVA-HANTAAN IgG EIA Enzyme immunoassay for detection of Dobrava and Hantaan IgG antibodies from human serum. Specificity 99%, Sensitivity 99%.
• Staining Solutions Wide range of staining solutions for hematology, microbiology, cytology and pathology applications. CE marked under IVDR. Manufactured according to EN ISO 9001:2015 certified quality system.
• Fixatives Pathology reagents including formol fixatives, ethanol fixatives, and PEG-ethanol fixatives for cytological samples.
• Ph. Eur. Reagents Ph.Eur compliant solutions including buffers, stabilizers, identification reagents, controls, calibrators, standards, and indicators for quality control, production and identification. Manufactured according to EN ISO 9001:2015 and EN ISO 13485:2016.
• Buffers and Liquid Solutions for Industry Industrial and laboratory solutions including PTB-traceable buffer solutions, NIST-traceable calibration buffers, indicators and volumetric solutions, phosphatise kits for dairy testing.
• Partnering and Contract Manufacturing Contract manufacturing of diagnostic products including reagents, controls, calibrators, and EIA plates for industrial customers. Services span from initial customer need to ready-to-use product with customized specifications, packaging, and labeling.
• Beckman Coulter Diagnostics (Distribution in Finland) Official exclusive distribution in Finland since 2019 of Beckman Coulter diagnostic products including clinical chemistry, immunochemistry, hematology, microbiology, urinalysis, and total laboratory automation solutions for hospitals, reference laboratories, and physician office settings.
• EUROIMMUN Products (Distribution in Finland) Exclusive distribution in Finland since 2018 of EUROIMMUN products (owned by PerkinElmer) including autoimmune diagnostics, infectious disease diagnostics, allergy diagnostics, and genetic analysis test systems.

Quantifiable outcome

• ReaScan+ PUUMALA IgM: PPA 99.3%, NPA 99.3% (275 samples); ReaScan TBE IgM: Specificity 98%, Sensitivity 99% (serum); ReaScan CXCL13: Specificity 96%, Sensitivity 100% (CSF); ReaScan+ LYME IgM/IgG Combo: PPA 94.8%, NPA 95.6%; Reagena C6 LYME IgM/IgG EIA: PPA 92.7%, NPA 95.9%
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature8 records

Partnerships

Five partnerships are on record, tiered minor and core.

• EU Rural Business Development Fund / ELY CentreminorOthers · 1 January 2025Reagena received funding from the EU Rural Business Development Fund (Maaseutuyritysten kehittämisrahasto) distributed by Ruokavirasto (Finnish Food Authority) and the ELY Centre in 2025. The funding supported internationalization efforts specifically targeting the Swiss market, including hiring a local diagnostic testing consultant and participating in sales and marketing events.
• Beckman Coulter DiagnosticscoreChannel Partner/ Reseller/ Distributor · 1 January 2019Reagena has been the official distributor for Beckman Coulter Diagnostics products in Finland since 2019. Beckman Coulter, an operating company of Danaher Corporation, provides clinical diagnostic systems including clinical chemistry, immunochemistry, hematology, microbiology, urinalysis, and total laboratory automation solutions used in hospitals, reference laboratories, and physician office settings worldwide.
• EUROIMMUN (PerkinElmer)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Reagena has been the exclusive distributor of EUROIMMUN products in Finland since 2018. EUROIMMUN, now owned by PerkinElmer, is a leading manufacturer of medical laboratory diagnostics. Reagena distributes EUROIMMUN products for autoimmune diseases, infectious diseases, allergies, and genetic analyses through its Finnish sales organization.
• International Distribution Partners (30+ countries)coreChannel Partner/ Reseller/ DistributorReagena has established distribution partnerships in over 30 countries. Key partners include: Selinion Medical (Belgium, Netherlands, Luxembourg), Arnika Srl (Italy), AlphaScience GmbH (Austria, Germany), Invitech Ltd (UK, Ireland), Aidian (Norway, Sweden, Denmark), Syngen Biotech (Poland), DiaSorin S.A. (France), Jasika d.o.o. (Croatia, Bosnia, Serbia), Laboserv s.r.o. (Slovakia, Czech Republic), Probo d.o.o. (Slovenia). For reagents: Mediq Suomi Oy, Pamark Oy (Finland, animal diagnostics), Immucor Ltd (UK, Ireland), Diachel Diagnostics S.A. (Greece), Erba Lachema s.r.o. (Slovakia, Czech Republic).
• Clinical and Research PartnersminorStrategic or Co-development PartnerReagena actively seeks collaboration with clinical laboratories and research institutions for clinical validation of new products. The company is looking for partners for scientific research projects and clinical testing in relation to tick-borne diseases and hantaviruses. Contact: CTO Ilpo Kuronen ([email protected]).

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• EUROIMMUN (PerkinElmer / Revvity): Global leader in autoimmune and infectious disease diagnostics whose products Reagena exclusively distributes in Finland. Comparable because of overlapping autoimmune and infectious disease IVD portfolios, though EUROIMMUN is far broader geographically and in product scope.
• Beckman Coulter Diagnostics (Danaher): Major clinical diagnostics platform (clinical chemistry, immunoassay, hematology, automation) whose products Reagena exclusively distributes in Finland. Comparable as a hospital-channel diagnostics vendor with overlapping customer base in Finnish hospitals and reference laboratories.
• DiaSorin: Italian-listed global IVD company with focus on immunodiagnostics and molecular diagnostics. Reagena's French distributor is DiaSorin S.A. Overlapping infectious disease and specialty immunoassay offerings make it a relevant comparable, though DiaSorin's scale is far larger.
• Immucor: Specialty transfusion and transplantation diagnostics company (acquired by IVD peers). Reagena distributes Immucor products in UK/Ireland for reagent customers. Comparable as a specialty IVD vendor operating in the same distribution-channel ecosystem.

Direct peers

• Aidian (formerly Orion Diagnostica): Finnish-origin IVD and POC diagnostics company spun out of Orion. Highly comparable: Nordic base, POC and rapid-test focus, similar heritage. Reagena's new CTO Mirko Brummer spent 20+ years at Orion Diagnostica/Aidian, indicating deep cultural and product overlap.
• Actim: Finnish rapid diagnostics company specializing in point-of-care tests. Comparable as a Finnish-headquartered IVD company with rapid-test focus; Reagena's new product development engineer Mika Laava previously held senior production and QA roles at Actim.

Emerging players

• NovaTec Immundiagnostica: German IVD manufacturer focused on infectious disease serology and EIA kits. Comparable because of overlapping immunoassay (EIA) diagnostic product lines for infectious disease, particularly relevant for Reagena's EIA Lyme and Puumala products.
• Mikrogen Diagnostik: German specialty IVD company with strong focus on tick-borne disease diagnostics (Lyme, TBE, FSME) and autoimmune serology. Highly comparable niche competitor in the same tick-borne disease segment that Reagena targets with its ReaScan+ Lyme and TBE products.
• Virotech Diagnostics: German IVD company specializing in serological infectious disease diagnostics including hantavirus, Borrelia, and tick-borne pathogens. Direct competitor in the same European niche of hantavirus and tick-borne disease serology that defines Reagena's core market.

Regional players

• AlphaScience GmbH: German specialty diagnostics distributor serving Austria and Germany that distributes Reagena products. Comparable as a regional infectious disease diagnostics channel player addressing similar hospital and laboratory customers in DACH.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/reagena

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reagena